
TRACON Pharmaceuticals TCON
Quartalsbericht 2024-Q2
hinzugefügt 13.08.2024
TRACON Pharmaceuticals P/S 2011-2026 | TCON
P/S Jährlich TRACON Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.489 | - | 138 | - | - | 7.28 | 5.66 | 17.6 | 10.7 | 31.3 | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 138 | 0.489 | 30.2 |
P/S anderer Aktien in der Pharmaeinzelhändler
| Name | P/S | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aquestive Therapeutics
AQST
|
10.5 | $ 4.12 | -0.36 % | $ 441 M | ||
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
2.65 | $ 8.32 | 3.67 % | $ 228 M | ||
|
Arcutis Biotherapeutics
ARQT
|
9.15 | $ 23.65 | 0.08 % | $ 3.01 B | ||
|
BioNTech SE
BNTX
|
35.7 | $ 91.44 | 0.29 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
BioXcel Therapeutics
BTAI
|
24 | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Burford Capital Limited
BUR
|
6.35 | $ 4.52 | 9.18 % | $ 683 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Cabaletta Bio
CABA
|
50.3 M | $ 3.1 | 4.56 % | $ 311 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
759 | $ 3.17 | 1.44 % | $ 6.9 B | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
0.935 | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Catalyst Biosciences
CBIO
|
8.57 | $ 19.48 | 0.39 % | $ 1.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Codexis
CDXS
|
1.57 | $ 1.95 | 6.87 % | $ 170 M | ||
|
Alpine Immune Sciences
ALPN
|
8.94 | - | - | $ 2.17 B | ||
|
Cerus Corporation
CERS
|
2.12 | $ 1.91 | 2.69 % | $ 364 M | ||
|
Cullinan Management
CGEM
|
35.1 | $ 15.11 | 4.71 % | $ 910 M | ||
|
Coherus BioSciences
CHRS
|
5.36 | $ 1.72 | -0.87 % | $ 201 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
10.4 | $ 0.46 | -13.02 % | $ 5.27 M | ||
|
Aravive
ARAV
|
6.61 | - | -13.39 % | $ 1.45 M | ||
|
Aptinyx
APTX
|
204 | - | -39.0 % | $ 4.57 M | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
2.17 | - | - | $ 96.9 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
5.16 | $ 24.95 | 1.05 % | $ 3.05 B | ||
|
Celldex Therapeutics
CLDX
|
1.32 K | $ 31.33 | 0.85 % | $ 2.08 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
2.86 | $ 10.27 | 0.98 % | $ 137 M | ||
|
Cardiff Oncology
CRDF
|
196 | $ 1.6 | 1.27 % | $ 107 M |